The X‐Ray Structure of Carboxypeptidase A Inhibited by a Thiirane Mechanism‐Based Inhibitor

The three‐dimensional X‐ray crystal structure of carboxypeptidase A, a zinc‐dependent hydrolase, covalently modified by a mechanism‐based thiirane inactivator, 2‐benzyl‐3,4‐epithiobutanoic acid, has been solved to 1.38 Å resolution. The interaction of the thiirane moiety of the inhibitor with the active site zinc ion promotes its covalent modification of Glu‐270 with the attendant opening of the thiirane ring. The crystal structure determination at high resolution allowed for the clear visualization of the covalent ester bond to the glutamate side chain. The newly generated thiol from the inhibitor binds to the catalytic zinc ion in a monodentate manner, inducing a change in the zinc ion geometry and coordination, while its benzyl group fits into the S1’ specificity pocket of the enzyme. The inhibitor molecule is distorted at the position of the carbon atom that is involved in the ester bond linkage on one side and the zinc coordination on the other. This particular type of thiirane‐based metalloprotease inhibitor is for the first time analyzed in complex to the target protease at high resolution and may be used as a general model for zinc‐dependent proteases.

[1]  D. Kim,et al.  Convenient Preparation of All Four Possible Stereoisomers of 2-Benzyl- 3,4-epoxybutanoic Acid, Pseudomechanism-Based Inactivator for Carboxypeptidase A via α-Chymotrypsin-Catalyzed Hydrolysis. , 2010 .

[2]  J. Witte,et al.  Carboxypeptidase 4 gene variants and early-onset intermediate-to-high risk prostate cancer , 2009, BMC Cancer.

[3]  F. Avilés,et al.  Aromatic Organic Compounds as Scaffolds for Metallocarboxypeptidase Inhibitor Design , 2009, Chemical biology & drug design.

[4]  E. Brunner,et al.  CPA6, FMO2, LGI1, SIAT1 and TNC are differentially expressed in early- and late-stage oral squamous cell carcinoma--a pilot study. , 2008, Oral oncology.

[5]  J. Fernández-Recio,et al.  Direct interaction between a human digestive protease and the mucoadhesive poly(acrylic acid). , 2008, Acta crystallographica. Section D, Biological crystallography.

[6]  James D. Johnson,et al.  Carboxypeptidase E mediates palmitate-induced β-cell ER stress and apoptosis , 2008, Proceedings of the National Academy of Sciences.

[7]  S. Mobashery,et al.  Conformational analyses of thiirane-based gelatinase inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[8]  A. Lambeir,et al.  Carboxypeptidase M Expressed by Human Bone Marrow Cells Cleaves the C‐Terminal Lysine of Stromal Cell‐Derived Factor‐1α: Another Player in Hematopoietic Stem/Progenitor Cell Mobilization? , 2008, Stem cells.

[9]  Z. Nemes,et al.  The presence of carboxypeptidase-M in tumour cells signifies epidermal growth factor receptor expression in lung adenocarcinomas , 2008, Journal of Cancer Research and Clinical Oncology.

[10]  Stewart B. Kirton,et al.  De Novo Ligand Design to Partially Flexible Active Sites: Application of the ReFlex Algorithm to Carboxypeptidase A, Acetylcholinesterase, and the Estrogen Receptor , 2008, J. Chem. Inf. Model..

[11]  Qingchun Zhou,et al.  Heme Regulates Exocrine Peptidase Precursor Genes in Zebrafish , 2007, Experimental biology and medicine.

[12]  D. Melton,et al.  A multipotent progenitor domain guides pancreatic organogenesis. , 2007, Developmental cell.

[13]  M. Blombäck,et al.  Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke , 2007, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[14]  F. Avilés,et al.  Nnal‐like proteins are active metallocarboxypeptidases of a new and diverse M14 subfamily , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  S. Satomura,et al.  Serum carboxypeptidase A activity as a biomarker for early-stage pancreatic carcinoma. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[16]  F. Avilés,et al.  Metallocarboxypeptidases: emerging drug targets in biomedicine. , 2007, Current pharmaceutical design.

[17]  N. Bruno,et al.  Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients. , 2006, Diabetes research and clinical practice.

[18]  S. Mobashery,et al.  Recent advances in MMP inhibitor design , 2006, Cancer and Metastasis Reviews.

[19]  J. Sánchez-Payá,et al.  Clinical value of rapid urine trypsinogen-2 test strip, urinary trypsinogen activation peptide, and serum and urinary activation peptide of carboxypeptidase B in acute pancreatitis. , 2005, World journal of gastroenterology.

[20]  C. Lillo,et al.  Carboxypeptidase E is required for normal synaptic transmission from photoreceptors to the inner retina , 2005, Journal of neurochemistry.

[21]  M. Bernardo,et al.  Potent Mechanism-based Inhibitors for Matrix Metalloproteinases* , 2005, Journal of Biological Chemistry.

[22]  C. K. Too,et al.  Characterization of a novel, cytokine-inducible carboxypeptidase D isoform in haematopoietic tumour cells. , 2005, The Biochemical journal.

[23]  S. Regnér,et al.  Active Carboxypeptidase B Is Present in Free Form in Serum from Patients with Acute Pancreatitis , 2005, Pancreatology.

[24]  N. Motoyama,et al.  Absence of Procarboxypeptidase R Induces Complement-Mediated Lethal Inflammation in Lipopolysaccharide-Primed Mice1 , 2004, The Journal of Immunology.

[25]  David C. Richardson,et al.  MOLPROBITY: structure validation and all-atom contact analysis for nucleic acids and their complexes , 2004, Nucleic Acids Res..

[26]  S. Gardell,et al.  Electrochemiluminescence assay for basic carboxypeptidases: inhibition of basic carboxypeptidases and activation of thrombin-activatable fibrinolysis inhibitor. , 2003, Analytical biochemistry.

[27]  K. J. Lee,et al.  The role of Tyr248 probed by mutant bovine carboxypeptidase A: insight into the catalytic mechanism of carboxypeptidase A. , 2001, Biochemistry.

[28]  L. Kotra,et al.  X-ray Absorption Studies of Human Matrix Metalloproteinase-2 (MMP-2) Bound to a Highly Selective Mechanism-based Inhibitor , 2001, The Journal of Biological Chemistry.

[29]  L. Kotra,et al.  Potent and Selective Mechanism-Based Inhibition of Gelatinases , 2000 .

[30]  W. Lipscomb,et al.  Recent Advances in Zinc Enzymology , 1997 .

[31]  William N. Lipscomb,et al.  Recent Advances in Zinc Enzymology. , 1996, Chemical reviews.

[32]  Sang J. Chung,et al.  INACTIVATION OF CARBOXYPEPTIDASE A BY 2-BENZYL-3,4-EPITHIOBUTANOIC ACID , 1995 .

[33]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[34]  Sangsoo Kim,et al.  The x-ray crystallographic study of covalently modified carboxypeptidase A by 2-benzyl-3,4-epoxybutanoic acid, a pseudomechanism-based inactivator , 1992 .

[35]  T. Plummer,et al.  A potent mercapto bi-product analogue inhibitor for human carboxypeptidase N. , 1981, Biochemical and biophysical research communications.

[36]  A. Lambeir,et al.  Carboxypeptidase M: Multiple alliances and unknown partners. , 2009, Clinica chimica acta; international journal of clinical chemistry.

[37]  J. Willemse,et al.  A role for procarboxypepidase U (TAFI) in thrombosis. , 2007, Frontiers in bioscience : a journal and virtual library.

[38]  朝井 鈴佳.  Absence of procarboxypeptidase R induces complement-mediated lethal inflammation in lipopolysaccharide-primed mice , 2005 .

[39]  L. Kotra,et al.  X-ray Absorption Studies of Human Matrix Metalloproteinase-2 (MMP-2) Bound to a Highly Selective Mechanism-based Inhibitor COMPARISON WITH THE LATENT AND ACTIVE FORMS OF THE ENZYME* , 2001 .

[40]  S. Ryu,et al.  Stereochemistry in inactivation of carboxypeptidase A. : structural analysis of the inactivated carboxypeptidase A by an enantiomeric pair of 2-benzyl-3,4-epoxybutanoic acids , 1997 .

[41]  Irina Massova,et al.  Crystallographic and computational insight on the mechanism of zinc-ion-dependent inactivation of carboxypeptidase a by 2-benzyl-3-iodopropanoate. , 1996 .

[42]  D. H. Kim,et al.  (2R, 3S)- and (2S, 3R)-2-Benzyl-3,4-epoxybutanoic acid as highly efficient and fast acting pseudomechanism-based inactivators for carboxypeptidase a: design, asymmetric synthesis and inhibitory kinetics , 1995 .

[43]  R. Wrigglesworth,et al.  Enzyme inhibitors in medicine. , 1989, Natural product reports.